ClinicalTrials.gg
RecruitingNCT06840886Updated Oct 5, 2026

A Study of PHST001 in Advanced Solid Tumors

A Phase 1 interventional study of PHST001 and Paclitaxel in Advanced Solid Tumors, Ovarian Cancer and Endometrial Cancer, sponsored by Pheast Therapeutics. Recruiting at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Pheast Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Oct 5, 2026Enrollment updatedEligibility revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
426
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms — 5 open to participants now, 8 under way, 1 of them phase 3. mirvetuximab soravtansine · Ovarian Neoplasms.

Planned enrollment
2nd of 12
426 · median 80
Started
2025
with 1 other
Phase 1
3 of 12
1 open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
Pheast Therapeutics

Among the 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 1, and was the 10th registered.

Ovarian Neoplasms

3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About mirvetuximab soravtansine

mirvetuximab soravtansine: first FDA approval 2022 (ELAHERE), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). Phase 1b will include the following cohorts 1) tumor-specific cohorts for participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma, 2) a randomized cohort for participants with ovarian cancer who will receive PHST001 in combination with mirvetuximab soravtansine, 3) a cohort for participants with advanced/metastatic breast cancer who will receive PHST001 in combination with trastuzumab deruxtecan and 4) a cohort of patients who consent to additional biomarker studies.

The study's primary objectives are to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 as monotherapy and in combination with anticancer therapies, as well as to assess the anti-tumor activity of PHST001 in combination with anticancer therapies in Phase 1b.

03

Conditions studied

  • Advanced Solid Tumors
  • Ovarian Cancer
  • Endometrial Cancer
  • Cholangiocarcinoma
  • CNS Tumor
  • Breast Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Carcinoma
  • Carcinosarcoma, Ovarian
04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • or cytologically confirmed advanced solid tumor which has from or been refractory to all locally available standard therapies.
  • Adequate organ function per laboratory testing
  • Pregnancy prevention requirements
  • per v1.1 (or RANO) as assessed by the local site Investigator/radiology
  • Performance status of 0 or 1 on (ECOG) scale

Key Exclusion Criteria:

  • Diagnosis of immunodeficiency
  • History of a previous additional , unless potentially curative treatment has been completed, with no evidence of malignancy for 2 years. Participants with basal cell carcinoma of the skin, Stage I melanoma, melanoma in situ, squamous cell carcinoma of the skin, early-stage prostate cancer, low grade neoplasms, or carcinoma in situ, excluding carcinoma in situ of the bladder, who have undergone potentially curative therapy are not excluded and can be enrolled regardless of disease-free period following completion of potentially curative therapy. Participants with early-stage breast cancer who have undergone curative intent treatment and with no disease recurrence for 2 years after treatment are not excluded.
  • Active known and/or carcinomatous meningitis from a systemic (non-CNS) primary malignancy. Participants with previously treated CNS metastases are eligible, provided they are radiologically and clinically stable (i.e., no evidence of progression for at least 2 weeks by repeat imaging performed during screening) and are not requiring systemic above the physiologic replacement for at least 7 days prior to the first dose of study treatment.
  • Received prior systemic anticancer therapy including agents within 21 days or, if shorter, within 5 half-lives prior to the first dose of study treatment. Participants must have recovered from all AEs due to previous therapies to Grade ≤1 or baseline. Participants with Grade ≤2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible.
  • Prior or allogeneic hematopoietic stem cell transplant or solid organ transplant.
  • Received previous treatment with another agent targeting CD24.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
426 participants (estimated)

Study arms

  • Experimental
    PHST001 Monotherapy

    Participants will receive PHST001 monotherapy administered once every 3 weeks (Q3W). In Phase 1a, PHST001 will be evaluated in sequential dose-escalation cohorts at planned dose levels of 0.1, 0.3, 1.0, 2.0, 4.0, 6.0, 9.0, 18.0, and 36.0 mg/kg. Dose levels may be modified or additional dose levels evaluated based on emerging safety, pharmacokinetic, pharmacodynamic, and antitumor activity data. Participants in the Phase 1b biomarker cohort may also receive PHST001 monotherapy.

    Biological: PHST001

  • Experimental
    PHST001 + Paclitaxel

    Participants will receive PHST001 in combination with paclitaxel. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in tumor-specific expansion cohorts, including participants with ovarian carcinoma, endometrial carcinoma, or cholangiocarcinoma, and/or in the biomarker cohort.

    Biological: PHST001 · Drug: Paclitaxel

  • Experimental
    PHST001 + Topotecan

    Participants will receive PHST001 in combination with topotecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or biomarker cohort.

    Biological: PHST001 · Drug: Topotecan

  • Experimental
    PHST001 + Doxorubicin

    Participants will receive PHST001 in combination with doxorubicin. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or endometrial carcinoma expansion cohorts and/or the biomarker cohort.

    Biological: PHST001 · Drug: Doxorubicin

  • Experimental
    PHST001 + FOLFIRI

    Participants will receive PHST001 in combination with FOLFIRI (5-fluorouracil, folinic acid, and irinotecan). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort.

    Biological: PHST001 · Drug: FOLFIRI

  • Experimental
    PHST001 + FOLFOX

    Participants will receive PHST001 in combination with FOLFOX (5-fluorouracil, folinic acid, and oxaliplatin). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort.

    Biological: PHST001 · Drug: FOLFOX

  • Experimental
    PHST001 + Gemcitabine

    Participants will receive PHST001 in combination with gemcitabine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or cholangiocarcinoma expansion cohorts and/or the biomarker cohort.

    Biological: PHST001 · Drug: Gemcitabine

  • Experimental
    PHST001 + Mirvetuximab Soravtansine

    Participants will receive PHST001 in combination with mirvetuximab soravtansine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or in the biomarker cohort. Half of the participants in the randomized ovarian carcinoma cohort may be randomly assigned to receive PHST001 in combination with mirvetuximab soravtansine.

    Biological: PHST001 · Biological: Mirvetuximab Soravtansine

  • Experimental
    PHST001 + Trastuzumab Deruxtecan

    Participants will receive PHST001 in combination with trastuzumab deruxtecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in participants with advanced or metastatic breast cancer and/or in the biomarker cohort.

    Biological: PHST001 · Biological: Trastuzumab Deruxtecan

  • Active comparator
    Mirvetuximab Soravtansine Monotherapy

    Participants with ovarian carcinoma enrolled in the randomized Phase 1b expansion cohort will be randomized 1:1 to receive mirvetuximab soravtansine monotherapy or mirvetuximab soravtansine in combination with PHST001. Participants assigned to this arm will receive mirvetuximab soravtansine monotherapy.

    Biological: Mirvetuximab Soravtansine

Interventions

  • BiologicalPHST001

    PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

  • Paclitaxel used as per standard of care.

    Also known as: Taxol

  • Topotecan used as per standard of care.

    Also known as: Hycamtin

  • Doxorubicin used as per standard of care.

    Also known as: Adriamycin

  • DrugFOLFIRI

    FOLFIRI used as per standard of care.

    Also known as: folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan combination

  • DrugFOLFOX

    FOLFOX used as per standard of care.

    Also known as: folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin combination

  • Gemcitabine used as per standard of care.

    Also known as: Gemzar

  • Mirvetuximab soravtansine used as per standard of care.

    Also known as: MIRV, Elahere

  • Trastuzumab deruxtecan used as per standard of care.

    Also known as: T-DXd, Enhertu

06

What researchers measure

Primary outcomes

  1. Frequency of Dose-Limiting Toxicities (DLTs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)

    Based on toxicities observed

    Time frame: From first dose of PHST001 through 21 days after the first dose of PHST001

  2. Frequency of Serious Adverse Events (SAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)

    Based on toxicities observed

    Time frame: From signed consent up to 90 days after the last dose of PHST001

  3. Frequency of Treatment Emergent Adverse Events (TEAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)

    Based on toxicities observed

    Time frame: From first dose up to 90 days after the last dose of PHST001

  4. Frequency of Treatment Related Adverse Events (TRAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)

    Based on toxicities observed

    Time frame: From first dose up to 90 days after the last dose of PHST001

  5. Frequency of Adverse Events of Special Interest (AESIs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)

    Based on toxicities observed

    Time frame: From first dose up to 90 days after the last dose of PHST001

  6. Frequency of AEs Leading to Dose Interruption or Treatment Discontinuation and AEs Leading to Death to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)

    Based on toxicities observed

    Time frame: From first dose up to 90 days after the last dose of PHST001

  7. Overall Response Rate (ORR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b non-randomized cohorts only)

    Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response.

    Time frame: From screening and during treatment up to 2 years

  8. Progression-Free Survival (PFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b randomized cohort only)

    Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first.

    Time frame: From screening and during treatment up to 2 years

Secondary outcomes

  1. Overall Response Rate (ORR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - randomized cohort only)

    Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response.

    Time frame: From screening and during treatment up to 2 years

  2. Duration of Response (DOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)

    Defined as time from date of first objective response (either CR or PR) to first documentation of radiographic disease progression.

    Time frame: From screening and during treatment up to 2 years

  3. Best Overall Response (BOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)

    Defined as the best response recorded for a participant across all time-point assessments from the start of treatment until disease progression or end of treatment.

    Time frame: From screening and during treatment up to 2 years

  4. Progression-Free Survival (PFS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - non-randomized cohorts only) .

    Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first.

    Time frame: From screening and during treatment up to 2 years

  5. Overall Survival (OS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b).

    Defined as the time from first dose of PHST001 to the date of death.

    Time frame: From screening and during treatment up to 2 years

  6. Maximum Observed Concentration (Cmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b).

    Defined as the maximum blood concentration of a dose of PHST001

    Time frame: From treatment until 90 days after last dose of PHST001

  7. Time to Maximum Concentration (tmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)

    Defined as the time required for a dose of PHST001 to reach its maximum blood concentration (Cmax) after administration.

    Time frame: From treatment until 90 days after last dose of PHST001

  8. Concentration at the End of a Dosing Interval (Ctrough) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)

    Defined as the blood concentration of a dose of PHST001 at the end of the dosing interval (just prior to next drug administration).

    Time frame: From treatment until 90 days after last dose of PHST001

  9. Area Under the Concentration-time Curve (AUC) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)

    Defined as the total PHST001 exposure over time, calculated as the integral of the plasma concentration-time profile.

    Time frame: From treatment until 90 days after last dose of PHST001

  10. Volume of Distribution at Steady-state (Vss) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)

    Defined as how widely PHST001 spreads throughout the body once things have stabilized after a dose has been administered.

    Time frame: From treatment until 90 days after last dose of PHST001

  11. Clearance (CL) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)

    Defined as the rate at which the body "cleans out" a dose of PHST001 from the bloodstream.

    Time frame: From treatment until 90 days after last dose of PHST001

  12. Terminal Elimination Half-life (t½) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)

    Defined as the time it takes for the amount of PHST001 in the body to drop by half during the final phase of elimination.

    Time frame: From treatment until 90 days after last dose of PHST001

07

Study locations

20 of 20 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Apr 2029, 49 months after the start.

Of 210 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 49 months is close to that.

Counting every sponsor, half of 380 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 21, 2025
StartActual
Mar 31, 2025
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2031
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
272→426
Oct 5, 2026
Eligibility
2 criteria edited
What changed in the criteria
  • EditedHistory of a previous additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 52 years. Participants with basal cell carcinoma of the skin, Stage I melanoma, melanoma in situ, squamous cell carcinoma of the skin, early-stage prostate cancer, low grade neoplasms, or carcinoma in situ, excluding carcinoma in situ of the bladder, who have undergone potentially curative therapy are not excluded and can be enrolled regardless of disease-free period following completion of potentially curative therapy. Participants with early-stage breast cancer who have undergone curative intent treatment and with no disease recurrence for 2 years after treatment are not excluded.
  • EditedActive known CNS metastases and/or carcinomatous meningitis from a systemic (non-CNS) primary malignancy. Participants with previously treated CNS metastases may participateare eligible, provided they are radiologically and clinically stable (i.e., withoutno evidence of progression for at least 2 weeks by repeat imaging [note that the repeat imaging should be performed during study screening]), clinically stable, and without requirement of steroid treatmentare not requiring systemic corticosteroids above the physiologic replacement for at least 147 days prior to the first dose of study treatment.
Oct 5, 2026
Interventions
Added Drug: Paclitaxel·Drug: Topotecan·Drug: Doxorubicin·Drug: FOLFIRI·Drug: FOLFOX·and 3 more
All 8

Drug: Paclitaxel · Drug: Topotecan · Drug: Doxorubicin · Drug: FOLFIRI · Drug: FOLFOX · Drug: Gemcitabine · Biological: Mirvetuximab Soravtansine · Biological: Trastuzumab Deruxtecan

; removed Drug: Chemotherapy per Standard of Care. Arms added: PHST001 Monotherapy·PHST001 + Paclitaxel·PHST001 + Topotecan·PHST001 + Doxorubicin·PHST001 + FOLFIRI·and 5 more
All 10

PHST001 Monotherapy · PHST001 + Paclitaxel · PHST001 + Topotecan · PHST001 + Doxorubicin · PHST001 + FOLFIRI · PHST001 + FOLFOX · PHST001 + Gemcitabine · PHST001 + Mirvetuximab Soravtansine · PHST001 + Trastuzumab Deruxtecan · Mirvetuximab Soravtansine Monotherapy

; arms removed: Dose Escalation (Phase 1a)·Dose Expansion (Phase 1b)
Oct 5, 2026
Primary outcomes
8 edited, 3 removed
What changed in the outcomes
  • EditedFrequency of Dose-Limiting Toxicities (DLTs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From first dose of PHST001 through 21 days after the first dose of PHST001
  • EditedFrequency of Serious Adverse Events (SAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From signed consent up to 90 days after the last dose of PHST001
  • EditedFrequency of Treatment Emergent Adverse Events (TEAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
  • EditedFrequency of Treatment Related Adverse Events (TRAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
  • EditedFrequency of Adverse Events of Special Interest (AESIs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
  • EditedFrequency of AEs Leading to Dose Interruption or Treatment Discontinuation and AEs Leading to Death to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
  • EditedOverall Response Rate (ORR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with chemotherapyanticancer therapy (Phase 1b non-randomized cohorts only)Time frame: From screening and during treatment up to 2 years
  • EditedDuration of ResponseProgression-Free Survival (DORPFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with chemotherapyanticancer therapy (Phase 1b randomized cohort only)Time frame: From screening and during treatment up to 2 years
  • RemovedBest Overall Response (BOR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with chemotherapy (Phase 1b)Time frame: From screening and during treatment up to 2 years
  • RemovedProgression-Free Survival (PFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with chemotherapy (Phase 1b)Time frame: From screening and during treatment up to 2 years
  • RemovedOverall Survival (OS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with chemotherapy (Phase 1b)Time frame: From screening and during treatment up to 2 years
Oct 5, 2026
Secondary outcomes
12 edited
What changed in the outcomes
  • EditedOverall Response Rate (ORR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - randomized cohort only)Time frame: From screening and during treatment up to 2 years
  • EditedDuration of Response (DOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)Time frame: From screening and during treatment up to 2 years
  • EditedBest Overall Response (BOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)Time frame: From screening and during treatment up to 2 years
  • EditedProgression-Free Survival (PFS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - non-randomized cohorts only) .Time frame: From screening and during treatment up to 2 years
  • EditedOverall Survival (OS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b).Time frame: From screening and during treatment up to 2 years
  • EditedMaximum Observed Concentration (Cmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b).Time frame: From treatment until 90 days after last dose of PHST001
  • EditedTime to Maximum Concentration (tmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From treatment until 90 days after last dose of PHST001
  • EditedConcentration at the End of a Dosing Interval (Ctrough) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From treatment until 90 days after last dose of PHST001
  • EditedArea Under the Concentration-time Curve (AUC) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From treatment until 90 days after last dose of PHST001
  • EditedVolume of Distribution at Steady-state (Vss) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From treatment until 90 days after last dose of PHST001
  • EditedClearance (CL) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From treatment until 90 days after last dose of PHST001
  • EditedTerminal Elimination Half-life (t½) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From treatment until 90 days after last dose of PHST001
Oct 5, 2026
Contact
Study contact changed: m•••@pheast.com · •••2349→m•••@pheast.com · •••8443. See the current contact
Oct 5, 2026
Site contacts
Changed at 19 sites. See the sites
Show 19 sites
  • Precision NextGen Oncology & Research Center · Beverly Hills, United StatesContact added J•••@nextgenonc.com · •••0708Contact added (no phone or email listed)
  • USC Norris Comprehensive Cancer Center · Los Angeles, United StatesContact added L•••@med.usc.eduContact added S•••@med.usc.edu
  • Stanford University School of Medicine · Palo Alto, United StatesContact added m•••@stanford.edu · •••7293Contact added (no phone or email listed)
  • Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One · Denver, United StatesContact added C•••@sarahcannon.com · •••2610
  • Yale Cancer Center · New Haven, United StatesContact added P•••@yale.edu · •••5564Contact added (no phone or email listed)
  • Dana Farber Cancer Institute · Boston, United StatesContact added d•••@dfci.harvard.eduContact added (no phone or email listed)
  • University of Michigan Rogel Cancer Center · Ann Arbor, United StatesContact added c•••@med.umich.edu · •••1125Contact added (no phone or email listed)
  • START Center for Cancer Research - Midwest · Grand Rapids, United StatesContact added h•••@startresearch.comContact added (no phone or email listed)
  • START Center for Cancer Research - Long Island New York · Lake Success, United StatesContact added s•••@startresearch.com · •••5166Contact added (no phone or email listed)
  • Mount Sinai · New York, United StatesContact added j•••@mssm.edu · •••7945Contact added (no phone or email listed)
  • Duke Cancer Institute · Durham, United StatesContact added P•••@duke.edu · •••6342Contact added (no phone or email listed)
  • Sarah Cannon Research Institute (SCRI) Oncology Partners · Nashville, United StatesContact added A•••@scresearch.net · •••7274Contact added (no phone or email listed)
  • Vanderbilt-Ingram Cancer Center · Nashville, United StatesContact added c•••@vumc.org · •••8480Contact added (no phone or email listed)
  • START Center for Cancer Research - Texas · Fort Worth, United StatesContact added h•••@startresearch.comContact added (no phone or email listed)
  • MD Anderson Cancer Center · Houston, United StatesContact added I•••@mdanderson.org · •••1930Contact added (no phone or email listed)
  • NEXT Oncology - Dallas · Irving, United StatesContact added n•••@nextoncology.com · •••4577Contact added (no phone or email listed)
  • START Center for Cancer Research - San Antonio · San Antonio, United StatesContact h•••@startresearch.com · •••5250→h•••@startresearch.com · •••5250
  • University of Texas (UT) Health · San Antonio, United StatesContact added m•••@uthscsa.eduContact added (no phone or email listed)
  • NEXT Oncology - Virginia · Fairfax, United StatesContact added a•••@nextoncology.comContact added c•••@usoncology.com
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Enrollment 272→426
    Eligibility 2 criteria edited
    What changed in the criteria
    • EditedHistory of a previous additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 52 years. Participants with basal cell carcinoma of the skin, Stage I melanoma, melanoma in situ, squamous cell carcinoma of the skin, early-stage prostate cancer, low grade neoplasms, or carcinoma in situ, excluding carcinoma in situ of the bladder, who have undergone potentially curative therapy are not excluded and can be enrolled regardless of disease-free period following completion of potentially curative therapy. Participants with early-stage breast cancer who have undergone curative intent treatment and with no disease recurrence for 2 years after treatment are not excluded.
    • EditedActive known CNS metastases and/or carcinomatous meningitis from a systemic (non-CNS) primary malignancy. Participants with previously treated CNS metastases may participateare eligible, provided they are radiologically and clinically stable (i.e., withoutno evidence of progression for at least 2 weeks by repeat imaging [note that the repeat imaging should be performed during study screening]), clinically stable, and without requirement of steroid treatmentare not requiring systemic corticosteroids above the physiologic replacement for at least 147 days prior to the first dose of study treatment.
    Primary outcomes 8 edited, 3 removed
    What changed in the outcomes
    • EditedFrequency of Dose-Limiting Toxicities (DLTs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From first dose of PHST001 through 21 days after the first dose of PHST001
    • EditedFrequency of Serious Adverse Events (SAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From signed consent up to 90 days after the last dose of PHST001
    • EditedFrequency of Treatment Emergent Adverse Events (TEAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
    • EditedFrequency of Treatment Related Adverse Events (TRAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
    • EditedFrequency of Adverse Events of Special Interest (AESIs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
    • EditedFrequency of AEs Leading to Dose Interruption or Treatment Discontinuation and AEs Leading to Death to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From first dose up to 90 days after the last dose of PHST001
    • EditedOverall Response Rate (ORR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with chemotherapyanticancer therapy (Phase 1b non-randomized cohorts only)Time frame: From screening and during treatment up to 2 years
    • EditedDuration of ResponseProgression-Free Survival (DORPFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with chemotherapyanticancer therapy (Phase 1b randomized cohort only)Time frame: From screening and during treatment up to 2 years
    • RemovedBest Overall Response (BOR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with chemotherapy (Phase 1b)Time frame: From screening and during treatment up to 2 years
    • RemovedProgression-Free Survival (PFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with chemotherapy (Phase 1b)Time frame: From screening and during treatment up to 2 years
    • RemovedOverall Survival (OS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with chemotherapy (Phase 1b)Time frame: From screening and during treatment up to 2 years
    Secondary outcomes 12 edited
    What changed in the outcomes
    • EditedOverall Response Rate (ORR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - randomized cohort only)Time frame: From screening and during treatment up to 2 years
    • EditedDuration of Response (DOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)Time frame: From screening and during treatment up to 2 years
    • EditedBest Overall Response (BOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)Time frame: From screening and during treatment up to 2 years
    • EditedProgression-Free Survival (PFS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - non-randomized cohorts only) .Time frame: From screening and during treatment up to 2 years
    • EditedOverall Survival (OS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b).Time frame: From screening and during treatment up to 2 years
    • EditedMaximum Observed Concentration (Cmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b).Time frame: From treatment until 90 days after last dose of PHST001
    • EditedTime to Maximum Concentration (tmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From treatment until 90 days after last dose of PHST001
    • EditedConcentration at the End of a Dosing Interval (Ctrough) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From treatment until 90 days after last dose of PHST001
    • EditedArea Under the Concentration-time Curve (AUC) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From treatment until 90 days after last dose of PHST001
    • EditedVolume of Distribution at Steady-state (Vss) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From treatment until 90 days after last dose of PHST001
    • EditedClearance (CL) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From treatment until 90 days after last dose of PHST001
    • EditedTerminal Elimination Half-life (t½) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with chemotherapyanticancer therapy (Phase 1b)Time frame: From treatment until 90 days after last dose of PHST001
    Interventions Added Drug: Paclitaxel·Drug: Topotecan·Drug: Doxorubicin·Drug: FOLFIRI·Drug: FOLFOX·and 3 more
    All 8

    Drug: Paclitaxel · Drug: Topotecan · Drug: Doxorubicin · Drug: FOLFIRI · Drug: FOLFOX · Drug: Gemcitabine · Biological: Mirvetuximab Soravtansine · Biological: Trastuzumab Deruxtecan

    ; removed Drug: Chemotherapy per Standard of Care. Arms added: PHST001 Monotherapy·PHST001 + Paclitaxel·PHST001 + Topotecan·PHST001 + Doxorubicin·PHST001 + FOLFIRI·and 5 more
    All 10

    PHST001 Monotherapy · PHST001 + Paclitaxel · PHST001 + Topotecan · PHST001 + Doxorubicin · PHST001 + FOLFIRI · PHST001 + FOLFOX · PHST001 + Gemcitabine · PHST001 + Mirvetuximab Soravtansine · PHST001 + Trastuzumab Deruxtecan · Mirvetuximab Soravtansine Monotherapy

    ; arms removed: Dose Escalation (Phase 1a)·Dose Expansion (Phase 1b)
    Contact Study contact changed: m•••@pheast.com · •••2349→m•••@pheast.com · •••8443. See the current contact
    Site contacts Changed at 19 sites. See the sites
    Show 19 sites
    • Precision NextGen Oncology & Research Center · Beverly Hills, United StatesContact added J•••@nextgenonc.com · •••0708Contact added (no phone or email listed)
    • USC Norris Comprehensive Cancer Center · Los Angeles, United StatesContact added L•••@med.usc.eduContact added S•••@med.usc.edu
    • Stanford University School of Medicine · Palo Alto, United StatesContact added m•••@stanford.edu · •••7293Contact added (no phone or email listed)
    • Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One · Denver, United StatesContact added C•••@sarahcannon.com · •••2610
    • Yale Cancer Center · New Haven, United StatesContact added P•••@yale.edu · •••5564Contact added (no phone or email listed)
    • Dana Farber Cancer Institute · Boston, United StatesContact added d•••@dfci.harvard.eduContact added (no phone or email listed)
    • University of Michigan Rogel Cancer Center · Ann Arbor, United StatesContact added c•••@med.umich.edu · •••1125Contact added (no phone or email listed)
    • START Center for Cancer Research - Midwest · Grand Rapids, United StatesContact added h•••@startresearch.comContact added (no phone or email listed)
    • START Center for Cancer Research - Long Island New York · Lake Success, United StatesContact added s•••@startresearch.com · •••5166Contact added (no phone or email listed)
    • Mount Sinai · New York, United StatesContact added j•••@mssm.edu · •••7945Contact added (no phone or email listed)
    • Duke Cancer Institute · Durham, United StatesContact added P•••@duke.edu · •••6342Contact added (no phone or email listed)
    • Sarah Cannon Research Institute (SCRI) Oncology Partners · Nashville, United StatesContact added A•••@scresearch.net · •••7274Contact added (no phone or email listed)
    • Vanderbilt-Ingram Cancer Center · Nashville, United StatesContact added c•••@vumc.org · •••8480Contact added (no phone or email listed)
    • START Center for Cancer Research - Texas · Fort Worth, United StatesContact added h•••@startresearch.comContact added (no phone or email listed)
    • MD Anderson Cancer Center · Houston, United StatesContact added I•••@mdanderson.org · •••1930Contact added (no phone or email listed)
    • NEXT Oncology - Dallas · Irving, United StatesContact added n•••@nextoncology.com · •••4577Contact added (no phone or email listed)
    • START Center for Cancer Research - San Antonio · San Antonio, United StatesContact h•••@startresearch.com · •••5250→h•••@startresearch.com · •••5250
    • University of Texas (UT) Health · San Antonio, United StatesContact added m•••@uthscsa.eduContact added (no phone or email listed)
    • NEXT Oncology - Virginia · Fairfax, United StatesContact added a•••@nextoncology.comContact added c•••@usoncology.com
    + 5 other changes: index terms, verification date, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06840886
Lead sponsor
Pheast Therapeutics
Responsible party
Sponsor
First posted
Feb 21, 2025
Start date
Mar 31, 2025
Primary completion
Apr 2029 (estimated)
Completion
Apr 2031 (estimated)
Last update
Oct 5, 2026

Study contacts

Raphaël Rousseau, Chief Medical Officer, PhD, MD
Contact
medical@pheast.com
650-260-8443

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirvetuximab soravtansine

Start the discussion